Overall, strenuous efforts made on the antihcv drug development are paying off with the development of four daas including boceprevir, telaprevir, sofosbuvir, and ledipasvir. Crossresistance between sofosbuvir, ledipasvir, and ribavirin has not been identified. Dose does not exceed ledipasvirsofosbuvir 90 mg400 mg 1 tablet per day. Variation assessment report as adopted by the chmp with all information of a commercially confidential nature deleted. Ledipasvir sofosbuvir dosage guide with precautions. Harvoni ledipasvirsofosbuvir dose, indications, adverse. Real world analysis of ledipasvirsofosbuvir harvoni.
Eleven of 440 patients had a virological relapse after the end of treatment. Efficacy and safety of ledipasvirsofosbuvir with and without ribavirin in patients with chronic hepatitis c virus genotype 1 infection. If you take harvoni with ribavirin, you should also read the medication guide for ribavirin. Costeffectiveness of hcv treatment with sofosbuvir and. Therapynaive genotype 1 patients without cirrhosis. It was approved in europe in november 2014 for treatment of adults with genotype 1 or 4 chronic. Whether and in which patients their improved efficacy justifies their increased cost is unclear. The ledipasvirsofosbuvir combination is a daa agent that interferes with hcv replication and can be used to treat patients without pegifn or ribavirin.
The use of harvoni for the treatment of chronic hepatitis c virus infection in patients with severe renal impairment including patients with end stage renal disease on. On august 28, 2019, the fda approved gileads harvoni. Ledipasvirsofosbuvir with or without ribavirin achieved svrs in the range of 9499%. It is a combination pill containing sofosbuvir sold separately as.
This medication is a combination of ledipasvir and sofosbuvir and is used to treat chronic longlasting hepatitis c, a viral infection of the liver. Ledipasvir 90 mg with sofosbuvir 400 mg qdledipasvir auc, cmin, cmax all v 34% sofosbuvir. Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis c virus hcv infection, are more efficacious and safer than the old standard of care osoc but are substantially more expensive. Ledipasvir and sofosbuvir plus ribavirin for treatment of hcv infection in patients with advanced liver disease. Svrs did not differ in patients receiving ledipasvirsofosbuvir with or without ribavirin. Harvoni is a fixeddose combination of ledipasvir, a hepatitis c virus. Efficacy and safety of ledipasvirsofosbuvir with and without. Hcv ns5a inhibitor, and sofosbuvir, an hcv nucleotide analog. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic hcv without cirrhosis. Ledipasvirsofosbuvir harvoni treatment hepatitis c online. What drugs, substances, or supplements interact with harvoni. Patient information harvoni harvoenee ledipasvir and. These prior approval supplemental new drug applications provide for the following.
Therapyexperienced patients have failed a peginterferon alfa with or without ribavirinbased regimen with or without an hcv protease inhibitor. Ledipasvir is a drug for the treatment of hepatitis c that was developed by gilead sciences. Harvoni is a fixeddose combination of ledipasvir, a hepatitis c virus hcv ns5a inhibitor, and sofosbuvir, an hcv nucleotide analog ns5b polymerase inhibitor, and is indicated for the treatment of chronic hepatitis c virus hcv in adults and pediatric patients 3 years of age and older. Ci, 95100% for 24 weeks of ledipasvir sofosbuvir, and 99% 95% ci, 95100% for 24 weeks of ledipasvirsofosbuvir plus ribavirin. Coadministered drug dose of drug dose of ledipasvirsofosbuvir effect on drug levels effect on ledipasvirsofosbuvir levels potential clinical effects. Seven of those patients came from the 12week ledipasvirsofosbuvir arm and four came from the 12week ledipasvir. Ledipasvirsofosbuvir generic brand hicl gcn exception. The ledipasvirsofosbuvir combination is a directacting antiviral agent that interferes with hcv replication and can be. Ledipasvir with sofosbuvir is recommended as an option for treating adults with chronic hepatitis c infection. Side effects of harvoni ledipasvir and sofosbuvir tablets. Harvoni ledipasvirsofosbuvir expanded orphan indication, new. Ledipasvir and sofosbuvir is a combination medicine used to treat chronic hepatitis c in adults and children who are at least 3 years old.
Harvoni combines the ns5a inhibitor ledipasvir with the nucleotide. The recommended dosage of harvoni is one tablet taken orally once daily with or without food. It is a combination pill containing sofosbuvir sold separately as sovaldi plus ledipasvir. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic hcv. In addition, ledipasvirsofosbuvir is indicated for the treatment of hepatitis c in persons coinfected with hiv. Ledipasvirsofosbuvir for 8 weeks can be considered in those who have pretreatment hcv rna less than 6 million international unitsml. Ribavirin must be administered with food, and if tolerated, the dose may be increased as follows. Ledipasvir and sofosbuvir is sometimes given in combination with another medicine called ribavirin ledipasvir and sofosbuvir treats specific genotypes of hepatitis c, and only in certain people. If a member had at least 56 days eight or more weeks of therapy they were considered a completer. The ledipasvir and sofosbuvir fixeddose combination tablet was initially approved for use. Extensively metabolized in liver to form the pharmacologically active nucleoside analog triphosphate gs461203. The addition of instructions for use ifu for the oral pellets to update the prescribing informations pi dosage and adminstration.
Ledipasvir is a potent inhibitor of hcv nonstructural protein 5a ns5a, a viral phosphoprotein that plays an important but poorly understood role in viral replication, assembly, and secretion. Ledipasvir and sofosbuvir for hcv in patients coinfected. The aim of this study was to evaluate the treatment outcome of ledipasvirsofosbuvir ldvsof for patients with chronic hepatitis c virus genotype 2 infection. Ledipasvir and sofosbuvir for untreated hcv genotype 1. Ledipasvir and sofosbuvir for 12 weeks for hepatitis c. Ledipasvirsofosbuvir is a preferred regimen for initial treatment and retreatment of patients with genotypes 1, 4, 5, or 6 chronic hepatitis c infection. The combination of sofosvubir and ledipasvir can be administered without regard to food. Hepatitis c treatment factsheet harvoni sofosbuvir. Harvoni is a twodrug fixeddose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet. The median terminal halflife of sofosbuvir following administration of ledipasvirsofosbuvir is 0. Sofosbuvir for 12 weeks in children 3 to aasld journals.
Ledipasvirsofosbuvir has limited potential for clinically significant drug interactions with most antiretroviral agents. If you miss a dose, take the missed dose as soon as you remember the same day. Ledipasvirsofosbuvir generic brand hicl gcn exceptionother ledipasvir sofo sbuvir harvoni 41457 this drug requires a written request for prior authorization. After completing phase iii clinical trials, on february 10, 2014 gilead filed for u. The median terminal halflife of ledipasvir in healthy volunteers following administration of ledipasvirsofosbuvir in the fasted state is 47 hours.
Ledipasvir and sofosbuvir are substrates of drug transporters pgp and bcrp while gs331007 is not. Johns wort may decrease ledipasvir and sofosbuvir plasma concentrations, leading to reduced therapeutic effect of harvoni, and the use with pgp inducers is not recommended with harvoni see. Harvoni ledipasvir and sofosbuvir tablet, film coated harvoni ledipasvir and sofosbuvir pellet gilead sciences, inchighlights of prescribing information these highlights do not include all the information needed to use harvoni safely and effectively. Ledipasvirsofosbuvir is approved for the treatment of chronic hepatitis c virus hcv genotype 1 infections in adults.
932 601 369 1551 1082 1392 1479 1484 191 143 807 1312 989 67 445 1349 1119 583 1237 90 1260 397 140 1194 1006 1142 310 398 1057 881 1113 1002 660 1149 969 517 257 536 97 1175 679 162 244 465 1273 1038